fig1

Figure 1. Management of endocrine-sensitive or de novo luminal ABC patients. For luminal ABC, endocrine-sensitive with or without targeted therapy remains the mainstay of treatment. Prior lines of therapy should be exhausted before initiating CT. Preferred therapeutic options are represented for women harboring specific gene mutations or without identified mutations. AI: Aromatase inhibitor; BRCA: breast cancer gene; CDK4/6i: cyclin-dependent kinase 4/6 inhibitors; CT: chemotherapy; ERS1: estrogen receptor 1; ET: endocrine therapy; ERBB2: v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; mut: mutated; PD: progressive disease; PFS: progression-free survival; SG: Sacituzumab govitecan; T-DXd: trastuzumab deruxtecan; wt: wild type; ABC: advanced breast cancer.